Other: normal saline ( DrugBank: - )

4 diseases

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01212094 (ClinicalTrials.gov)	September 2010	29/9/2010	Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)	Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)	Multiple Sclerosis	Drug: Rituximab;Other: normal saline	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Terminated	18 Years	65 Years	All	44	Phase 1/Phase 2	United States

臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02592798 (ClinicalTrials.gov)	March 1, 2016	29/10/2015	Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)	A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease)	Nephrotic Syndrome;Focal Segmental Glomerulosclerosis;Minimal Change Disease	Drug: Abatacept;Other: Normal Saline;Other: D5W	Bristol-Myers Squibb	NULL	Completed	6 Years	N/A	All	36	Phase 2	United States

臨床試験数 : 143 / 薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00823030 (ClinicalTrials.gov)	January 2009	14/1/2009	Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis	Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis	Interstitial Cystitis	Procedure: Urodynamic study;Drug: Lidocaine;Other: Normal Saline	North Shore Long Island Jewish Health System	NULL	Withdrawn	18 Years	80 Years	Both	0	N/A	United States
2	NCT00194610 (ClinicalTrials.gov)	May 2004	13/9/2005	Botox as a Treatment for Interstitial Cystitis in Women	Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial	Painful Bladder Syndrome;Interstitial Cystitis	Drug: Botox;Other: normal saline	University of Washington	Paul G. Allen Family Foundation	Completed	18 Years	N/A	Female	20	Phase 4	United States

臨床試験数 : 25 / 薬物数 : 29 - (DrugBank : 15) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 153

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03076099 (ClinicalTrials.gov)	January 1, 2016	6/3/2017	Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation Embolization	Effects of Dexmedetomidine on Post-operative Blood Pressure in Patients Undergoing Brain Arteriovenous Malformation Embolization	Anesthesia	Drug: Dexmedetomidine;Other: normal saline	Nan Jiang	NULL	Recruiting	18 Years	65 Years	All	30	N/A	China